(Q36806669)

16 August 2017

1 reference

title

Clinical trials in Parkinson's disease dementia and dementia with Lewy bodies (English)

1 reference

Parkinson's disease dementia

16 August 2017

0 references

1 reference

1 reference

Richard Camicioli

1

1 reference

16 August 2017

Serge Gauthier

series ordinal

2

1 reference

16 August 2017

publication date

1 March 2007

1 reference

Canadian Journal of Neurological Sciences

16 August 2017

published in

1 reference

16 August 2017

volume

34 Suppl 1

1 reference

16 August 2017

page(s)

S109-17

1 reference

Striatal monoamine terminals in Lewy body dementia and Alzheimer's disease

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005679

Functional imaging in Parkinson's disease and dementia with Lewy bodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005679

Regional cerebral blood flow in Parkinson's disease with and without dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005679

Posterior cingulate metabolic changes occur in Parkinson's disease patients without dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005679

Proton magnetic resonance spectroscopy in dementia with Lewy bodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005679

Progressive brain atrophy on serial MRI in dementia with Lewy bodies, AD, and vascular dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005679

Volumetric MRI study of the caudate nucleus in patients with dementia with Lewy bodies, Alzheimer's disease, and vascular dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005679

Dementia with Lewy bodies and AD are not associated with occipital lobe atrophy on MRI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005679

MRI study of caudate nucleus volume in Parkinson's disease with and without dementia with Lewy bodies and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005679

Atrophy of the putamen in dementia with Lewy bodies but not Alzheimer's disease: an MRI study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005679

Parkinson's disease is associated with hippocampal atrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005679

Cerebral atrophy in Parkinson's disease with and without dementia: a comparison with Alzheimer's disease, dementia with Lewy bodies and controls.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005679

Topography, Extent, and Clinical Relevance of Neurochemical Deficits in Dementia of Lewy Body Type, Parkinson's Disease, and Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005679

More than just two peas in a pod: common amyloidogenic properties of tau and alpha-synuclein in neurodegenerative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005679

The apathy inventory: assessment of apathy and awareness in Alzheimer's disease, Parkinson's disease and mild cognitive impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005679

Cornell Scale for Depression in Dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005679

Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005679

Clinical, neuropsychological, and morphometric correlates of apathy in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005679

Apathy in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005679

Cognitive and motor function in patients with Parkinson's disease with and without depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005679

Effects of depression and Parkinson's disease on cognitive functioning.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005679

Effect of psychiatric and other nonmotor symptoms on disability in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005679

A comparative study of psychiatric symptoms in dementia with Lewy bodies and Parkinson's disease with and without dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005679

Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005679

Rivastigmine for dementia associated with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005679

Neuroleptic sensitivity in dementia with Lewy bodies and Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005679

Development of a functional measure for persons with Alzheimer's disease: the disability assessment for dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005679

DLB fluctuations: specific features that reliably differentiate DLB from AD and normal aging.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005679

Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005679

Fluctuating cognition in dementia with Lewy bodies and Alzheimer's disease is qualitatively distinct

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005679

Long-term benefits of rivastigmine in dementia associated with Parkinson's disease: an active treatment extension study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005679

Encephalopathy in a patient with previous malignancy but normal brain imaging.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005679

Successful use of donepezil for the treatment of psychotic symptoms in patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005679

Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson's disease: a case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005679

Effects of rivastigmine on the quantitative EEG in demented Parkinsonian patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005679

Eligibility of Alzheimer's disease clinic patients for clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005679

A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005679

The evaluation of disease modifying therapies in Alzheimer's disease: a regulatory viewpoint

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005679

Effects of rivastigmine on cognitive function in dementia with lewy bodies: a randomised placebo-controlled international study using the cognitive drug research computerised assessment system

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005679

Strategies for disease modification in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005679

Executive control function: a review of its promise and challenges for clinical research. A report from the Committee on Research of the American Neuropsychiatric Association.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005679

Disease modification in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005679

Assessment of cognition in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005679

Rivastigmine (Exelon) for dementia in patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005679

Validity of the Dementia Rating Scale in assessing cognitive function in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005679

Worsening of motor function and mood in a patient with Parkinson's disease after pharmacologic challenge with oral rivastigmine

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005679

A comparison of the efficacy of donepezil in Parkinson's disease with dementia and dementia with Lewy bodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005679

Influence of Alzheimer pathology on clinical diagnostic accuracy in dementia with Lewy bodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005679

What happens when donepezil is suddenly withdrawn? An open label trial in dementia with Lewy bodies and Parkinson's disease with dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005679

REM sleep behavior disorder in Parkinson's disease and dementia with Lewy bodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005679

Donepezil for dementia in Parkinson's disease: a randomised, double blind, placebo controlled, crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005679

Performance on the dementia rating scale in Parkinson's disease with dementia and dementia with Lewy bodies: comparison with progressive supranuclear palsy and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005679

The beneficial effect of cholinesterase inhibitors on patients suffering from Parkinson's disease and dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005679

Delusions and hallucinations in dementia with Lewy bodies: worsening with memantine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005679

Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005679

Memantine in moderate-to-severe Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005679

The role of levodopa in the management of dementia with Lewy bodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005679

L-dopa responsiveness in dementia with Lewy bodies, Parkinson disease with and without dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005679

Association of REM sleep behavior disorder and neurodegenerative disease may reflect an underlying synucleinopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005679

Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005679

Aripiprazole for drug-induced psychosis in Parkinson disease: preliminary experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005679

Long‐term outcome of quetiapine use for psychosis among parkinsonian patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005679

Conceptualization of mild cognitive impairment: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005679

Clinical predictors of response to Acetyl Cholinesterase Inhibitors: experience from routine clinical use in Newcastle

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005679

Semantic memory is impaired in both dementia with Lewy bodies and dementia of Alzheimer's type: a comparative neuropsychological study and literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005679

Hallucinations predict attentional improvements with rivastigmine in dementia with lewy bodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005679

Systematic review and meta-analysis show that dementia with Lewy bodies is a visual-perceptual and attentional-executive dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005679

Alleviation of multiple abnormalities by galantamine treatment in two patients with dementia with Lewy bodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005679

Efficacy and safety of galantamine in patients with dementia with Lewy bodies: a 12-week interim analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005679

Comparison of dementia with Lewy bodies to Alzheimer's disease and Parkinson's disease with dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005679

Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005679

Olanzapine treatment for dopaminergic-induced hallucinations

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005679

Acetylcholinesterase inhibition in dementia with Lewy bodies: results of a prospective pilot trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005679

Efficacy of quetiapine in Parkinson's patients with psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005679

Quetiapine improves psychotic symptoms and cognition in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005679

Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005679

A systematic review of the efficacy and safety of atypical antipsychotics in patients with psychological and behavioral symptoms of dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005679

Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005679

Practice Parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005679

Synucleinopathy pathology and REM sleep behavior disorder plus dementia or parkinsonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005679

Extrapyramidal features in Parkinson's disease with and without dementia and dementia with Lewy bodies: A cross-sectional comparative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005679

What best differentiates Lewy body from Alzheimer's disease in early-stage dementia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005679

Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005679

Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005679

Dementia with Lewy bodies: response of delirium-like features to donepezil.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005679

Comparative value of brain perfusion SPECT and [(123)I]MIBG myocardial scintigraphy in distinguishing between dementia with Lewy bodies and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005679

Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005679

Striatal dopamine transporter in dementia with Lewy bodies and Parkinson disease: a comparison.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005679

Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005679

Combined 123I-FP-CIT and 123I-IBZM SPECT for the diagnosis of parkinsonian syndromes: study on 72 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005679

Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005679

Detection of mild cognitive deficits in Parkinson's disease patients with the WAIS-R NI.

21 January 2018

2 references

https://api.crossref.org/works/10.1017%2FS0317167100005679

21 January 2018

https://api.crossref.org/works/10.1017%2FS0317167100005679

7 January 2021

Pentagon drawing and neuropsychological performance in Dementia with Lewy Bodies, Alzheimer's disease, Parkinson's disease and Parkinson's disease with dementia

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005679

Quetiapine for psychosis in Parkinson's disease versus dementia with Lewy bodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005679

7 January 2021

Dementia in Parkinson disease: a proton magnetic resonance spectroscopy study

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005679

7 January 2021

Intellectual, mnemonic, and frontal functions in dementia with Lewy bodies: A comparison with early and advanced Parkinson's disease

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005679

7 January 2021

Better cognitive and psychopathologic response to donepezil in patients prospectively diagnosed as dementia with Lewy bodies: a preliminary study

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005679

7 January 2021

Long-Term use of rivastigmine in patients with dementia with Lewy bodies: an open-label trial

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005679

7 January 2021

Clozapine for the treatment of drug-induced psychosis in Parkinson's disease: results of the 12 week open label extension in the PSYCLOPS trial

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005679

7 January 2021

Cholinesterase inhibition in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005679

7 January 2021

The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005679

7 January 2021

Reliability and validity of the Delis-Kaplan Executive Function System: an update.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005679

7 January 2021

Fluctuations in attention: PD dementia vs DLB with parkinsonism

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005679

7 January 2021

Donepezil for treatment of dementia with Lewy bodies: a case series of nine patients

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005679

7 January 2021

Competency to consent to medical treatment in cognitively impaired patients with Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005679

7 January 2021

Cognitive slowing in Parkinson's and Alzheimer's patients: distinguishing bradyphrenia from dementia

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005679

7 January 2021

Benefits of rivastigmine on attention in dementia associated with Parkinson disease

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005679

7 January 2021

The use of memantine in dementia with Lewy bodies.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005679

7 January 2021

Exclusion of Elderly Subjects From Clinical Trials for Parkinson Disease

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005679

7 January 2021

A comparison of episodic memory deficits in neuropathologically-confirmed Dementia with Lewy bodies and Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005679

7 January 2021

Cerebrospinal fluid markers in dementia with lewy bodies compared with Alzheimer disease

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005679

7 January 2021

Donepezil for dementia with Lewy bodies: a case study

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005679

7 January 2021

Dementia with lewy bodies: findings from an international multicentre study.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005679

7 January 2021

Rivastigmine in the treatment of dementia with Lewy bodies: preliminary findings from an open trial.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005679

7 January 2021

Dementia with Lewy bodies treated with rivastigmine: effects on cognition, neuropsychiatric symptoms, and sleep.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005679

7 January 2021

Severe worsening of parkinsonism in Lewy body dementia due to donepezil

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005679

7 January 2021

10.1017/S0317167100005679

Identifiers

DOI

1 reference

16 August 2017

1 reference